3 ms·
> The long-acting and ultra-fast formulations people actually use when given a choice. The patent for insulin glargine (Lantus) and insulin aspart (NovoLog) ex
by jrflowers 1y ago
> The long-acting and ultra-fast formulations people actually use when given a choice.
The patent for insulin glargine (Lantus) and insulin aspart (NovoLog) expired over a decade ago, though kind of amusingly Sanofi holds an active patent on “putting more Lantus in a vial than you usually would”
https://patents.google.com/patent/US9345750B2/en https://patents.google.com/patent/US9345750B2/en
I could be wrong but off the top of my head the only insulin I can think of that’s probably under patent is Afrezza, which is cool as hell because it’s inhalable and ultra-quick
- JumpCrisscross 1y agoIt’s less the patent per se than the production cost. A lot of cost estimates use the 1980s Humalin or whatnot as their baseline. I’m not diabetic. But everyone I know who is doesn’t like that one. So we need to know the cost for the medicines folks are actually taking.
- jrflowers 1y agoIt looks like the cost to manufacture modern biosimilars could be around $2-6 per vial. https://gh.bmj.com/content/3/5/e000850 https://gh.bmj.com/content/3/5/e000850
- s1artibartfast 1y agoCost to manufacture obviously isnt the only factor.